Timolol implant - EyeD Pharma
Alternative Names: Intraocular implant releasing timolol - EyeD Pharma; TimoD; TimoD implant; Timolol releasing intraocular implant - EyeD PharmaLatest Information Update: 02 Apr 2024
At a glance
- Originator EyeD Pharma
- Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Small molecules; Thiadiazoles
- Mechanism of Action Beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Open-angle glaucoma
Most Recent Events
- 01 Mar 2024 Phase-I clinical trials in Open-angle glaucoma in Belgium, Germany (Intraocular) (NCT06321562)
- 01 Mar 2024 Preclinical trials in Open-angle glaucoma in Belgium (Intraocular) before March 2024